Table 5

Studies evaluating populations in resource-rich settings with access to ART

Author	Year	Study location	Total number of participants	% HIV+	HIV+ on ART (%)	% undetectable HIV plasma load	Mean/median blood CD4	% HIV+ smokers	% HIV− smokers	Definition of cough	% HIV+ with cough	% HIV− with cough	Definition of breathlessness	% HIV+ with breathlessness	% HIV− with breathlessness
Drummond27 ALIVE cohort	2010	USA	974	30	54	16.5	320	83	86	Cough present	3	29	MRC dyspnoea score ≥2	35	28
										Morning cough ≥4 days per week	19	19
										Morning cough ≥3 months	15	15
Crothers8 Lung HIV Study	2013	USA	589	51	89	84	493	47	35	Unusual cough	28	20	MRC dyspnoea score ≥2	15	11
Fitzpatrick7 WIHS	2013	USA	99	64	81	NS	426	46	50				Dyspnoea	35	31
Madeddu30	2013	Italy	176	63	78	71	541	57	58	Cough	32	14	MRC dyspnoea score ≥2	31	15
Campo32 EXHALE substudy, VACS cohort	2014	USA	340	53	89	NS	431	64	58	Chronic cough	25	16	MRC dyspnoea score ≥2	25	16
Gingo33 MACS	2014	USA	1896	48	77	70	572	31	23	Cough	42	38	Dyspnoea	14	9
Gingo WIHS	2014	USA	1976	71	76	56	502	39	52	Cough	54	58	Dyspnoea	36	37

ART, antiretroviral therapy; MACS, Multi-Centre AIDS Cohort Study; VACS, Veterans Aging Cohort Study; WIHS, Women's Interagency HIV Study.